Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemoradiation in Elderly ESCC
NCT06061146Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06061146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061146.